Balyasny Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-372,793
| Closed | -$6.71M | – | 1719 |
|
|
2020
Q2 | $6.71M | Buy |
+372,793
| New | +$5.19M | 0.06% | 436 |
|
|
2020
Q1 | – | Sell |
-278,043
| Closed | -$6.64M | – | 1662 |
|
|
2019
Q4 | $6.64M | Buy |
278,043
+66,154
| +31% | +$1.82M | 0.04% | 525 |
|
|
2019
Q3 | $5.68M | Buy |
211,889
+78,508
| +59% | +$2.2M | 0.04% | 523 |
|
|
2019
Q2 | $3.62M | Buy |
+133,381
| New | +$4.18M | 0.02% | 703 |
|
|
2018
Q2 | – | Sell |
-15,449
| Closed | -$505K | – | 2319 |
|
|
2018
Q1 | $505K | Buy |
+15,449
| New | +$678K | ﹤0.01% | 1439 |
|
|
2017
Q4 | – | Sell |
-5,300
| Closed | -$286K | – | 2447 |
|
|
2017
Q3 | $286K | Sell |
5,300
-319,900
| -98% | -$18.8M | ﹤0.01% | 1554 |
|
|
2017
Q2 | $18.3M | Sell |
325,200
-310,445
| -49% | -$12.4M | 0.08% | 339 |
|
|
2017
Q1 | $24.9M | Buy |
+635,645
| New | +$20.2M | 0.12% | 233 |
|
|
2016
Q3 | – | Sell |
-388,026
| Closed | -$9.16M | – | 1372 |
|
|
2016
Q2 | $9.16M | Buy |
388,026
+121,539
| +46% | +$3M | 0.06% | 374 |
|
|
2016
Q1 | $5.44M | Sell |
266,487
-232,651
| -47% | -$7.38M | 0.03% | 521 |
|
|
2015
Q4 | $25.7M | Buy |
+499,138
| New | +$24.2M | 0.18% | 165 |
|
Balyasny Asset Management's PTLA Position: Q3 2020 in Review
Balyasny Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 372,793 shares — an estimated $6.71M sold.
Balyasny Asset Management first reported a position in PTLA in Q4 2015 and held it in 11 quarters. The position peaked at $25.7M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Balyasny Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Balyasny Asset Management sold 372,793 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $6.71M.
- Balyasny Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 11 quarters.
- Balyasny Asset Management's Portola Pharmaceuticals, Inc. position peaked at $25.7M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Balyasny Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.